Find Funding Opportunities

National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Mental Health (NIMH) and the National Institute on Aging (NIA) intend to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to invite exploratory and innovative researchapplications focused on theneurological and neuropsychiatric manifestationsof COVID-19 (neuro-COVID) andPost-Acute Sequelae of SARS-CoV-2 Infection (neuro-PASC) and on the effect of COVID-19 on pre-infection neurologic conditions. Applications investigating the pathophysiology and mechanisms of neuro-COVID and neuro-PASC and neurologically-focused human subjects research, as well as those proposing studies of scientifically compelling pathways to prevent the development of neuro-PASC or to accelerate the development of effective treatments forPASC-related neurological complications are of particular interest for this FOA. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in the first quarter of 2023 with an expected application due date in late Spring 2023. This FOA will utilize the R21 activity code. Details of the planned FOA are provided below.

National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Mental Health (NIMH) and the National Institute on Aging (NIA) intend to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to invite exploratory and innovative researchapplications focused on theneurological and neuropsychiatric manifestationsof COVID-19 (neuro-COVID) andPost-Acute Sequelae of SARS-CoV-2 Infection (neuro-PASC) and on the effect of COVID-19 on pre-infection neurologic conditions. Applications investigating the pathophysiology and mechanisms of neuro-COVID and neuro-PASC and neurologically-focused human subjects research, as well as those proposing studies of scientifically compelling pathways to prevent the development of neuro-PASC or to accelerate the development of effective treatments forPASC-related neurological complications are of particular interest for this FOA. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in the first quarter of 2023 with an expected application due date in late Spring 2023. This FOA will utilize the R01 activity code. Details of the planned FOA are provided below.

The COVID-19 pandemic continues to be the source of much mortality and morbidity creating and contributing to both physical and mental health issues. Recent data suggest that over 825,000 individuals have died from COVID-19 in the United States including over 8600 deaths in the week ending January 5, 2022.However, the impact of the SARS-CoV-2 virus as well as the associated measures to prevent and treat this infection extend well beyond the issue of mortality. Although much needed information regarding the epidemiology, transmission and potential acute treatments including the development of an effective vaccine have been gleaned in unprecedented time, important issues remain to be elucidated including, but not limited to the effect of the virus and its therapy on menstrual health, fertility and the offspring of infected and/or vaccinated parents, the impact of the relatively recent Delta and Omicron variants and other emerging variants, the occurrence of viral co-infections and the many physical and mental health issues created by the pandemic itself.